{"id":"W4308057391","doi":"10.1182/bloodadvances.2022008216","title":"Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia","year":2022,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Gilead Sciences; Servier; National Cancer Institute; Regeneron Pharmaceuticals; National Institutes of Health; Sunesis; MacroGenics; Astellas Pharma; Juno Therapeutics; Sierra Oncology; Pfizer; Incyte; CTI Biopharma; Agios Pharmaceuticals; Pharmacyclics; Jazz Pharmaceuticals; PTC Therapeutics; Celgene; Alexion Pharmaceuticals; TG Therapeutics; Amgen; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Dasatinib; Medicine; Blinatumomab; Prednisone; Minimal residual disease; Internal medicine; Maintenance therapy; Oncology; Chemotherapy; Leukemia; Lymphoblastic Leukemia; Imatinib","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001009775,0.0004466963,0.001196395,0.000230654,0.0001752629,0.0004687095,0.000309657,0.0003266453,0.001182401],"category_scores_gemma":[0.0004936438,0.0001767397,0.0006241885,0.0002941354,0.000297027,0.0003903597,0.000334839,0.001115262,0.0002747251],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003974085,"about_ca_system_score_gemma":0.0006315663,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002702461,"about_ca_topic_score_gemma":0.001031832,"domain_scores_codex":[0.9995586,0.0002253019,0.00005857637,0.00004833908,0.0000509959,0.00005813621],"domain_scores_gemma":[0.9997866,0.00004215671,0.00006514265,0.00001934566,0.00001192411,0.00007480738],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5702914,0.01563166,0.01310945,0.001386041,0.001276653,0.0003561123,0.0002171557,0.004554794,0.04827164,0.0005392419,0.001443902,0.3429219],"study_design_scores_gemma":[0.3149109,0.6121711,0.03208653,0.0001616737,0.00121956,0.001415033,0.0001259284,0.004061106,0.02146397,0.0006075026,0.01172832,0.0000482611],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9942734,0.00388969,0.0003472291,0.0001350642,0.00005891222,0.000363457,0.0001365218,0.00002663137,0.000769072],"genre_scores_gemma":[0.9959527,0.002125113,0.0006283033,0.0001451974,0.00003844003,0.0002908143,0.0002264374,0.000005357664,0.0005875367],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001196395,"threshold_uncertainty_score":0.005340278,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01038593191246425,"score_gpt":0.2800741377065346,"score_spread":0.2696882057940704,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}